BURLINGTON, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in four upcoming investor conferences in March.
Oppenheimer 34th Annual Healthcare MedTech & Services Conference (Virtual)
Tuesday, March 12, 2024
David Roberts, President, will present at 11:20 AM EDT
Barclays Global Healthcare Conference
Thursday, March 14, 2024
Loews Miami Beach Hotel, Miami Beach, FL
David Roberts, President, will present at 10:15 AM EDT
36th Annual Roth Conference 2024
Tuesday, March 19, 2024
The Ritz Carlton, Laguna Niguel located in Dana Point, CA
JJ Pellegrino, Chief Financial Officer, will present at 11 AM PDT
KeyBanc Life Sciences & MedTech Investor Forum (Virtual)
Wednesday, March 20, 2024
David Roberts, President, will present at 11:15 AM EDT
About LeMaitre
LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. For more information about the Company, please visit www.lemaitre.com.
LeMaitre is a registered trademark of LeMaitre Vascular, Inc.
Last Trade: | US$86.28 |
Daily Change: | 1.61 1.90 |
Daily Volume: | 182,235 |
Market Cap: | US$1.940B |
April 01, 2025 February 27, 2025 December 16, 2024 October 31, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load